Zenas BioPharma (ZBIO) Total Non-Current Liabilities (2023 - 2026)

Zenas BioPharma's Total Non-Current Liabilities history runs 4 years deep, the most recent figure standing at $350.7 million for Q1 2026.

• On a quarterly basis, Total Non-Current Liabilities changed N/A year-over-year to $350.7 million in Q1 2026; TTM through Mar 2026 was $350.7 million, a N/A change from a year earlier, with the FY2025 full-year figure at $78.8 million, up 36068.35% from the prior year.
• Total Non-Current Liabilities climbed to $350.7 million in Q1 2026 per ZBIO's latest filing, from $78.8 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $350.7 million in Q1 2026 and bottomed at $218000.0 in Q4 2024.
• The 4-year median for Total Non-Current Liabilities is $73.2 million (2025), against an average of $105.3 million.
• Across the five-year window, Total Non-Current Liabilities plunged 99.07% in 2024 and soared 36068.35% in 2025, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $23.5 million in 2023, then plunged by 99.07% to $218000.0 in 2024, then surged by 36068.35% to $78.8 million in 2025, then soared by 344.78% to $350.7 million in 2026.
• Per Business Quant, the three latest ZBIO Total Non-Current Liabilities figures stand at $350.7 million (Q1 2026), $78.8 million (Q4 2025), and $73.2 million (Q3 2025).